Impact of skeletal complications on patients' quality of life, mobility, and functional independence

Supportive Care in Cancer

Volumn 16, Issue 8, 2008, Pages 879-889

  Costa, Luis ^a   Badia, Xavier ^b   Chow, Edward ^c   Lipton, Allan ^d   Wardley, Andrew ^e  

^a HOSPITAL DE SANTA MARIA   (Portugal)

^b Health Economics and Outcomes Research   (Spain)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^d PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^e CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Bone metastases; Bone pain; Breast cancer; Prostate cancer; Zoledronic acid

Indexed keywords

ANALGESIC AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CYTOTOXIC AGENT; DOCETAXEL; ESTRAMUSTINE; HORMONE; IBANDRONIC ACID; MITOXANTRONE; PAMIDRONIC ACID; PLACEBO; PREDNISONE; ZOLEDRONIC ACID;

ADVANCED CANCER; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER GROWTH; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; EXTERNAL BEAM RADIOTHERAPY; FUNCTIONAL ASSESSMENT; FUNCTIONAL DISEASE; HUMAN; MEDICAL INFORMATION; MORBIDITY; MULTIPLE MYELOMA; OSTEOPOROSIS; PALLIATIVE THERAPY; PATHOLOGIC FRACTURE; PATIENT MOBILITY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SPINAL CORD COMPRESSION; TREATMENT OUTCOME; TREATMENT RESPONSE;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HEALTH STATUS; HUMANS; IMIDAZOLES; MALE; PAIN; PROSTATIC NEOPLASMS; QUALITY OF LIFE;

EID: 48349127751     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-008-0418-0     Document Type: Review

References (77)

1. NK Aaronson S Ahmedzai B Bergman M Bullinger A Cull NJ Duez A Filiberti H Flechtner SB Fleishman JC de Haes 1993 The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 365 376
2. E Adrover J Allepuz A Sureda M Domine A Barnadas M Constela A Lluch M Ruiz J Piera JI Mayordomo A Morales M Muñoz J Alcover R Colomer A Llombart B Massutti J Carballido R Garrido R Garcia X Badia L Lizan M Gilabert 2005 Development of a questionnaire to measure health-related quality of life (HRQoL) in patients with bone metastases (BOMET-QoL) J Outcomes Res 9 15 27
3. M Arianayagam J Chang P Rashid 2007 Chemotherapy in the treatment of prostate cancer-is there a role? Aust Fam Physician 36 737 739
4. G Aus CC Abbou M Bolla A Heidenreich HP Schmid H van Poppel J Wolff F Zattoni 2005 EAU guidelines on prostate cancer Eur Urol 48 546 551
5. SM Bang SH Park HG Kang JI Jue IH Cho YH Yun EK Cho DB Shin JH Lee 2005 Changes in quality of life during palliative chemotherapy for solid cancer Support Care Cancer 13 515 521
6. RL Barkin SJ Barkin DS Barkin 2005 Perception, assessment, treatment, and management of pain in the elderly Clin Geriatr Med 21 465 490 v
7. JR Berenson BE Hillner RA Kyle K Anderson A Lipton GC Yee JS Biermann 2002 American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma J Clin Oncol 20 3719 3736
8. JR Berenson A Lichtenstein L Porter MA Dimopoulos R Bordoni S George A Lipton A Keller O Ballester M Kovacs H Blacklock R Bell JF Simeone DJ Reitsma M Heffernan J Seaman RD Knight 1998 Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group J Clin Oncol 16 593 602
9. DL Berry CM Moinpour CS Jiang DP Ankerst DP Petrylak LV Vinson PN Lara S Jones ME Taplin PA Burch MHA Hussain ED Crawford 2006 Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone J Clin Oncol 24 2828 2835
10. ML Bianchi MR Orsini S Saraifoger S Ortolani G Radaelli S Betti 2005 Quality of life in post-menopausal osteoporosis Health Qual Life Outcomes 3 78
11. JJ Body IJ Diel R Bell M Pecherstorfer MR Lichinitser AF Lazarev D Tripathy B Bergstrom 2004 Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer Pain 111 306 312
12. JJ Body IJ Diel MR Lichinitser ED Kreuser W Dornoff VA Gorbunova M Budde B Bergstrom 2003 Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases Ann Oncol 14 1399 1405
13. ST Bogardus Jr V Towle CS Williams MM Desai SK Inouye 2001 What does the medical record reveal about functional status? A comparison of medical record and interview data J Gen Intern Med 16 728 736
14. Cancer Research UK (2007) Bone mets newsletter 03: April 2007. Available at: http://www.ucl.ac.uk/cancertrials/trials/rib/Spring%2007.pdf. Accessed December 20, 2007
15. DF Cella DS Tulsky G Gray B Sarafian E Linn A Bonomi M Silberman SB Yellen P Winicour J Brannon 1993 The Functional Assessment of Cancer Therapy scale: development and validation of the general measure J Clin Oncol 11 570 579
16. E Chow JS Wu P Hoskin LR Coia SM Bentzen PH Blitzer 2002 International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases Radiother Oncol 64 275 280
17. CS Cleeland KM Ryan 1994 Pain assessment: global use of the Brief Pain Inventory Ann Acad Med Singapore 23 129 138
18. Clemons M, Dranitsaris G, Ooi W, Cole DE (2007) A phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. Breast Cancer Res Treat [Epub ahead of print]
19. MJ Clemons G Dranitsaris WS Ooi G Yogendran T Sukovic BY Wong S Verma KI Pritchard M Trudeau DE Cole 2006 Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy J Clin Oncol 24 4895 4900
20. RE Coleman 1997 Skeletal complications of malignancy Cancer 80 suppl 1588 1594
21. RE Coleman 2004 Bisphosphonates: clinical experience Oncologist 9 suppl 4 14 27
22. RJ Cook P Major 2001 Methodology for treatment evaluation in patients with cancer metastatic to bone J Natl Cancer Inst 93 534 538
23. M Deschamps PR Band AJ Coldman 1988 Assessment of adult cancer pain: shortcomings of current methods Pain 32 133 139
24. IJ Diel 2007 Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review Support Care Cancer 15 1243 1249
25. IJ Diel JJ Body MR Lichinitser ED Kreuser W Dornoff VA Gorbunova M Budde B Bergstrom 2004 Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer Eur J Cancer 40 1704 1712
26. Eastham J, McKiernan J, Gleason D, Zheng M, Saad F Effect of zoledronic acid on bone pain and skeletal morbidity in patients with advanced prostate cancer: analysis by baseline pain [poster]. Presented at: 41st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, Florida. Abstract 4561
27. E Efstathiou G Bozas A Kostakopoulos E Kastritis C Deliveliotis N Antoniou D Skarlos C Papadimitriou MA Dimopoulos A Bamias 2005 Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment Urology 65 126 130
28. I Elomaa T Kylmala T Tammela J Viitanen J Ottelin M Ruutu K Jauhiainen M Ala-Opas L Roos J Seppanen 1992 Effect of oral clodronate on bone pain. A controlled study in patients with metastatic prostatic cancer Int Urol Nephrol 24 159 166
29. DS Ernst IF Tannock EW Winquist PM Venner L Reyno MJ Moore K Chi K Ding C Elliott W Parulekar 2003 Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain J Clin Oncol 21 3335 3342
30. European Organisation for Research and Treatment of Cancer (2007) EORTC Quality of Life Group projects. Available at: http://www.eortc.be/home/qol/ QLGProjects.htm. Accessed July 31, 2007
31. EuroQol Group 1990 EuroQol-a new facility for the measurement of health-related quality of life Health Policy 16 199 208
32. F Fulfaro A Casuccio C Ticozzi C Ripamonti 1998 The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials Pain 78 157 169
33. F Fulfaro G Leto G Badalamenti C Arcara G Cicero MR Valerio G Di Fede A Russo A Vitale GB Rini A Casuccio C Intrivici N Gebbia 2005 The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers J Chemother 17 555 559
34. Harris K, Chow E (2006) Bone metastases module. Available at: http://www.eortc.be/home/qol/Presentations%20of%20past%20meetings/ Southampton%20Nov%202006/Chow_Bone_mets_module_short_Nov2006.pdf. Accessed July 31, 2007
35. A Heidenreich A Elert R Hofmann 2002 Ibandronate in the treatment of prostate cancer associated painful osseous metastases Prostate Cancer Prostatic Dis 5 231 235
36. A Heidenreich R Hofmann UH Engelmann 2001 The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer J Urol 165 136 140
37. A Heidenreich C Ohlmann P Olbert A Hegele 2003 High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer [abstract] Eur J Cancer Suppl 1 suppl S270 Abstract 897
38. F Hering PRT Rodrigues M Lipay 2003 Clodronate for treatment of bone metastases in hormone refractory prostate cancer Int Braz J Urol 29 228 233
39. BE Hillner JN Ingle RT Chlebowski J Gralow GC Yee NA Janjan JA Cauley BA Blumenstein KS Albain A Lipton S Brown 2003 American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer J Clin Oncol 21 4042 4057
40. GN Hortobagyi RL Theriault A Lipton L Porter D Blayney C Sinoff H Wheeler JF Simeone JJ Seaman RD Knight M Heffernan K Mellars DJ Reitsma 1998 Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group J Clin Oncol 16 2038 2044
41. PJ Hoskin 2004 The RIB trial Clin Oncol (R Coll Radiol) 16 445 446
42. SP Jagdev OP Purohit S Heatley C Herling RE Coleman 2001 Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease Ann Oncol 12 1433 1438
43. A Jemal R Siegel E Ward T Murray J Xu C Smigal MJ Thun 2006 Cancer statistics, 2006 CA Cancer J Clin 56 106 130
44. N Kinnane 2007 Burden of bone disease Eur J Oncol Nurs 11 suppl 2 S28 S31
45. N Kohno K Aogi H Minami S Nakamura T Asaga Y Iino T Watanabe C Goessl Y Ohashi S Takashima 2005 Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial J Clin Oncol 23 3314 3321
46. P Lips NM van Schoor 2005 Quality of life in patients with osteoporosis Osteoporos Int 16 447 455
47. A Lipton 2005 Management of bone metastases in breast cancer Curr Treat Options Oncol 6 161 171
48. A Lipton RL Theriault GN Hortobagyi J Simeone RD Knight K Mellars DJ Reitsma M Heffernan JJ Seaman 2000 Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials Cancer 88 1082 1090
49. I Mancini JC Dumon JJ Body 2004 Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study J Clin Oncol 22 3587 3592
50. EL Mayer HJ Burstein 2007 Chemotherapy for metastatic breast cancer Hematol Oncol Clin North Am 21 257 272
51. HD Menssen A Sakalova A Fontana Z Herrmann C Boewer T Facon MR Lichinitser CR Singer L Euller-Ziegler M Wetterwald D Fiere M Hrubisko E Thiel PD Delmas 2002 Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma J Clin Oncol 20 2353 2359
52. N O'Rourke E McCloskey F Houghton H Huss JA Kanis 1995 Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases J Clin Oncol 13 929 934
53. E Ozyuvaci A Altan C Demir 2005 [The effects of clodronate for the pain treatment of bone metastasis due to prostate cancer] Agri 17 49 53
54. I Pande DL Scott TW O'Neill C Pritchard AD Woolf MJ Davis 2006 Quality of life, morbidity, and mortality after low trauma hip fracture in men Ann Rheum Dis 65 87 92
55. C Ripamonti E Fagnoni T Campa V Giardina C Brunelli F De Conno 2006 Pain on movement and pain on rest decrease after zoledronic acid infusion in patients with bone metastases due to breast or prostate cancer [abstract] J Clin Oncol 24 suppl 694s Abstract 18582
56. P Rodrigues F Hering JC Campagnari 2004 Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients Prostate Cancer Prostatic Dis 7 350 354
57. LS Rosen D Gordon NS Tchekmedyian R Yanagihara V Hirsh M Krzakowski M Pawlicki P De Souza M Zheng G Urbanowitz D Reitsma J Seaman 2004 Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial Cancer 100 2613 2621
58. Saad F, Gleason D, Murray R, Venner P, Tchekmedyian NS, Lacombe L, Chin J, Vinholes J, Goas JA, Chen B-L, Seaman J (2003) Zoledronic acid is well tolerated for up to 24 months and significantly reduces skeletal complications in patients with advanced prostate cancer metastatic to bone [poster]. Presented at: American Urological Association Annual Meeting; April 26-May 1, 2003; Chicago, Illinois. Abstract 1472
59. F Saad DM Gleason R Murray S Tchekmedyian P Venner L Lacombe JL Chin JJ Vinholes JA Goas B Chen 2002 A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 94 1458 1468
60. F Saad DM Gleason R Murray S Tchekmedyian P Venner L Lacombe JL Chin JJ Vinholes JA Goas M Zheng 2004 Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer J Natl Cancer Inst 96 879 882
61. A Santangelo M Testai P Barbagallo S Manuele A Di Stefano M Tomarchio G Trizzino G Musumeci P Panebianco D Maugeri 2006 The use of bisphosphonates in palliative treatment of bone metastases in a terminally ill, oncological elderly population Arch Gerontol Geriatr 43 187 192
62. EJ Small MR Smith JJ Seaman S Petrone MO Kowalski 2003 Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer J Clin Oncol 21 4277 4284
63. H Sonoo K Shimozuma J Kurebayashi K Ohta T Kiyono 1995 [Systemic therapy, pain relief and quality of life of breast cancer patients with bone metastasis] Gan To Kagaku Ryoho 22 suppl 1 10 15
64. WO Spitzer AJ Dobson J Hall E Chesterman J Levi R Shepherd RN Battista BR Catchlove 1981 Measuring the quality of life of cancer patients: a concise QL-index for use by physicians J Chronic Dis 34 585 597
65. Stanculeanu DL, Minea LN, Cringeaunu A, Anghel R (2006) Zoledronic acid treatment in osteocondensant bone metastasis prostate cancer patients [abstract]. Presented at: 2006 ASCO Prostate Cancer Symposium; February 24-26, 2006; San Francisco, California. Abstract 289
66. A Sureda D Isla JM Cozar M Ruiz M Domine M Margeli E Adrover M Ramos M Pastor A Martin A Llombart B Massutti M Munoz A Barnadas J Fernandez R Colomer J Allepuz M Gilabert X Badia 2007 Final development and validation of the BOMET-QoL questionnaire for assessing quality of life in patients with malignant bone disease due to neoplasia J Med Econ 10 27 39
67. RL Theriault A Lipton GN Hortobagyi R Leff S Gluck JF Stewart S Costello I Kennedy J Simeone JJ Seaman RD Knight K Mellars M Heffernan DJ Reitsma 1999 Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group J Clin Oncol 17 846 854
68. J Tidermark N Zethraeus O Svensson H Tornkvist S Ponzer 2002 Femoral neck fractures in the elderly: functional outcome and quality of life according to EuroQol Qual Life Res 11 473 481
69. A Trombetti F Herrmann P Hoffmeyer MA Schurch JP Bonjour R Rizzoli 2002 Survival and potential years of life lost after hip fracture in men and age-matched women Osteoporos Int 13 731 737
70. M Tubiana-Hulin P Beuzeboc L Mauriac N Barbet M Frenay A Monnier JM Pion O Switsers JL Misset S Assadourian E Bessa 2001 Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases Bull Cancer 88 701 707
71. V Vassiliou C Kalogeropoulou C Christopoulos E Solomou M Leotsinides D Kardamakis 2007 Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment Int J Radiat Oncol Biol Phys 67 264 272
72. V Vassiliou C Kalogeropoulou E Giannopoulou M Leotsinidis I Tsota D Kardamakis 2007 A novel study investigating the therapeutic outcome of patients with lytic, mixed and sclerotic bone metastases treated with combined radiotherapy and ibandronate Clin Exp Metastasis 24 169 178
73. JJF Vinholes OP Purohit ME Abbey R Eastell RE Coleman 1997 Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease Ann Oncol 8 1243 1250
74. CL Vogel RH Yanagihara AJ Wood FM Schnell C Henderson BH Kaplan MH Purdy R Orlowski JL Decker L Lacerna JA Hohneker 2004 Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy Oncologist 9 687 695
75. A Wardley N Davidson P Barrett-Lee A Hong J Mansi D Dodwell R Murphy T Mason D Cameron 2005 Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration Br J Cancer 92 1869 1876
76. KP Weinfurt LD Castel Y Li JW Timbie GA Glendenning KA Schulman 2004 Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions Med Care 42 164 175
77. KP Weinfurt Y Li LD Castel F Saad JW Timbie GA Glendenning KA Schulman 2005 The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer Ann Oncol 16 579 584